Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015

Laut, Kristina Grønborg; Shepherd, Leah; Rădoi, Roxana; Karpov, Igor; Parczewski, Miłosz; Mussini, Cristina; Maltêz, Fernando; Losso, Marcelo; Chkhartishvili, Nikoloz; Elinav, Hila; Kovari, Helen; Blaxhult, Anders; Zangerle, Robert; Trofimova, Tatiana; Inglot, Małgorzata; Zilmer, Kai; Kuzovatova, Elena; Staub, Thérèse; Raben, Dorthe; Lundgren, Jens D; Mocroft, Amanda; Kirk, Ole

doi:10.2807/1560-7917.es.2018.23.21.1700382

Cited by 14 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are currently data on over 22 000 HIV‐positive individuals aged ≥ 16 years from 100 centres in 36 European countries, Israel and Argentina. These countries were categorized into regions, as in previous publications :…”

Section: Methodsmentioning

confidence: 99%

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA

Amele

Peters

Sluzhynska³

et al. 2019

HIV Medicine

View full text Add to dashboard Cite

Objectives The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)‐coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct‐acting antiviral (DAA) therapy. Methods Stages included in the continuum were as follows: anti‐HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow‐up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow‐up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Results Numbers and percentages for the stages of the HCV continuum of care were as follows: anti‐HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow‐up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). Conclusions In the proposed HCV continuum of care for HIV/HCV‐coinfected individuals, we found major gaps at all stages, with almost 20% of anti‐HCV‐positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre‐DAA era.

show abstract

Section: Methodsmentioning

confidence: 99%

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA

Amele

Peters

Sluzhynska³

et al. 2019

HIV Medicine

View full text Add to dashboard Cite

show abstract

“…Geographical region was categorised as in previous EuroSIDA analyses 27 . Due to low numbers, Australia was combined with Northern Europe in the analysis models, and Eastern Central Europe was combined with Eastern Europe.…”

Section: A C C E P T E Dmentioning

confidence: 99%

Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

Greenberg

Ryom

Wandeler

et al. 2020

JAIDS Journal of Acquired Immune Deficiency Syndromes

Self Cite

View full text Add to dashboard Cite

Background Despite increased INSTI use, limited large-scale, real-life data exists on INSTI uptake and discontinuation. Setting International multicohort collaboration. Methods RESPOND participants starting dolutegravir (DTG), elvitegravir (EVG) or raltegravir (RAL) after 1/1/2012 were included. Predictors of INSTI used were assessed using multinomial logistic regression. Kaplan Meier and Cox proportional hazards models describe time to and factors associated with discontinuation. Results Overall, 9702 persons were included; 5051 (52.1%) starting DTG, 1933 (19.9%) EVG, 2718 (28.0%) RAL. The likelihood of starting RAL or EVG versus DTG decreased over time and was higher in Eastern and Southern Europe compared to Western Europe.

show abstract

“…The percentage of people receiving ART has changed over time, overall and by region. A Study by Lau et al showed that in 2014-2015, 22% of HIV-positive patients in Europe did not receive ART [19]. In low-and middle-income countries, two-thirds of HIV/AIDS-related deaths occur in individuals not on ART [20] 20 .…”

Section: Discussionmentioning

confidence: 99%

Trends of HIV Mortality between 2001 and 2018: An Observational Analysis

et al. 2021

View full text Add to dashboard Cite

Since the beginning of the epidemic in the early 1980s, HIV-related illnesses have led to the deaths of over 32.7 million individuals. The objective of this study was to describe current mortality rates for HIV through an observational analysis of HIV mortality data from 2001 to 2018 from the World Health Organization (WHO) Mortality Database. We computed age-standardized death rates (ASDRs) per 100,000 people using the World Standard Population. We plotted trends using locally weighted scatterplot smoothing (LOWESS). Data for females were available for 42 countries. In total, 31/48 (64.60%) and 25/42 (59.52%) countries showed decreases in mortality in males and females, respectively. South Africa had the highest ASDRs for both males (467.7/100,000) and females (391.1/100,000). The lowest mortalities were noted in Egypt for males (0.2/100,000) and in Japan for females (0.01/100,000). Kyrgyzstan had the greatest increase in mortality for males (+6998.6%). Estonia had the greatest increase in mortality for females (+5877.56%). The disparity between Egypt (the lowest) and South Africa (the highest) was 3042-fold for males. Between Japan and South Africa, the disparity was 43,454-fold for females. Although there was a decrease in mortality attributed to HIV among most of the countries studied, a rising trend remained in a number of developing countries.

show abstract

Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015

Cited by 14 publications

References 22 publications

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA

Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

Trends of HIV Mortality between 2001 and 2018: An Observational Analysis

Contact Info

Product

Resources

About